Endometrial cancer and tamoxifen. Discussion based on a case series;Cancer de l'endometre et tamoxifene. Discussion a partir d'une serie de cas

Bulletin du Cancer

Volumn 84, Issue 1, 1997, Pages 51-60

  Sasco, Annie J ^a   Ah Song, Roland ^a   Gendre, Isabelle ^a   Zlatoff, Patrick ^b   Bobin, Jean Yves ^c   Hallonet, Philippe ^d   Leduc, Bernard ^e  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Clinique Charcot   (France)

^c HÔPITAL DU BOCAGE   (France)

^d Clinique de Monplaisir   (France)

^e Centre Hospitalier de Brive   (France)

Author keywords

breast cancer; endometrial cancer; rare histological forms; tamoxifen

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; ENDOMETRIUM CANCER; FEMALE; HISTOLOGY; HUMAN; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; FOLLOW UP; FRANCE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 0030630898     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Altaras MM, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol 1993; 49: 255-8.
2. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83: 1013-7.
3. Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 1992; 31: 259-63.
4. Anteoy E, Yagel S, Zacut D, Palti Z, Hochner Celnikier D. False sonographic appearance of endometrial neoplasia in postmenopausal women treated with tamoxifen. Lancet 1992; 340: 433-4.
5. Anzai Y, Holinka CF, Kuramoto H, Gurpide E. Stimulatory effects of 4-hydroxytamofixen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res 1989; 49: 2362-5.
6. Bardi M, Arnoldi E, Pizzocchero G, Pezzica L, Mattioni D, Perotti M. Endometrioid carcinoma in pelvic endometriosis in a postmenopausal woman with tamoxifen adjuvant therapy for breast cancer. A case report. Eur J Gynaecol Oncol 1994; 15: 393-5.
7. Boudouris O, Ferrand S, Guillet JL, Madelenat P. Effets paradoxaux du tamoxifène sur l'utérus de la femme. À propos de sept cas de myomes apparus sous traitement anti-œstrogénique. J Gynecol Obstet Biol Reprod Paris 1989; 18: 372-8.
8. Brooks JJ, Wheeler JE. Malignancy arising in extragonadal endometriosis: a case report and summary of the world literature. Cancer 1977; 40: 3065-73.
9. Buckley CH. Tamoxifen and endometriosis. Case report. Br J Obstet Gynaecol 1990; 97: 645-6.
10. Cano A, Matallini P, Legua V, Tortajada M, Bonilla-Musoles F. Tamoxifen and endometriosis. Lancet 1989; ii: 376.
11. Clarke MR. Uterine malignant mixed mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer. Gynecol Oncol 1993; 51: 411-5.
12. Cohen I, Rosen DJ, Tepper R, Cordoba M, Shapira Y, Altaras MM, Yigael D, Beyth Y. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993; 12: 275-80.
13. Cohen I, Altaras MM, Lew S, Tepper R, Beyth Y, Ben Baruch G. Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature. Gynecol Oncol 1994; 55: 443-7.
14. Cohen I, Beyth Y, Tepper R, Shapira J, Zalel Y, Figer A, Cordoba M, Yigael D, Beyth D, Altaras MM. Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol 1996; 60: 54-8.
15. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers. J Natl Cancer Instit 1995; 87: 1359-64.
16. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992; 79: 111-6.
17. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant tamoxifen therapy for breast cancer. Brief communication. J Natl Cancer Inst 1996; 88: 832-4.
18. Cuzick J. Chemoprevention of breast cancer with tamoxifen. In: Hakama M, Beral V, Buiatti E, Faivre J, Parkin DM, eds. Chemoprevention in cancer control. No 136. Lyon: International Agency for Research on Cancer, 1996; 95-109.
19. Dallenbach Hellweg G, Hahn U. Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Pathol 1995; 14: 7-15.
20. De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G, De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 1991; 36: 127-30.
21. Deprest J, Neven P, Ide P. An unusual type of endometrial cancer, related to tamoxifen? Eur J Obstet Gynecol Reprod Biol 1992; 46: 147-50.
22. Dilts PV Jr, Hopkins MP, Chang AE, Cody RL. Rapid growth of leiomyoma in patient receiving tamoxifen. Am J Obstet Gynecol 1992; 166: 167-8.
23. EBCTCG. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
24. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, Askergren J, Hjalmar MI. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.
25. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-20.
26. Fornander T, Rutqvist LE, Wilking N, Carlstrom K, von Schoultz B. Estrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer 1993; 29A: 497-500.
27. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205.
28. Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R, Tancer ML. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer-preliminary report. Gynecol Oncol 1991; 42: 120-3.
29. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170: 447-51.
30. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987; 47: 4020-4.
31. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48: 812-5.
32. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993; 53: 3919-24.
33. Hajjar LR, Kim W, Nolan GH, Turner S, Raju UR. Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: report of a case. Obstet Gynecol 1993; 82: 642-4.
34. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl: CD(BR) rats. Cancer Res 1993; 53: 4534-41.
35. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri [letter]. Lancet 1988a; 2: 563.
36. Hardell L. Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri [letter]. Lancet 1988b; 2: 1432.
37. Hardell L. Tamoxifen as risk factor for endometrial cancer. Cancer 1990; 66: 1661.
38. Helzlsouer KJ, Bush T. More on endometrial cancer and tamoxifen. J Natl Cancer Inst 1994; 86: 1877.
39. IARC. International Agency for Research on Cancer. IARC Monograph on the evolution of carcinogenic risk to humans. Some pharmaceutical drugs. IARC Monograph, vol. 66. Lyon: International Agency for Research on Cancer, 1996.
40. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994; 47: 827-33.
41. Jordan VC, Allen KE. Evaluation of the antitumour activity of the nonsteroidal antiestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980; 16: 239-51.
42. Jose R, Kekre AN, George SS, Seshadri L. Endometrial carcinoma in a tamoxifen-treated breast cancer patient. Aust NZ J Obstet Gynaecol 1995; 35: 201.
43. Lahti E, Blanco G, Kauppila A, Apaja Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660-4.
44. Leo L, Lanza A, Re A, Tessarolo M, Bellino R, Lauricella A, Wierdis T. Leiomyomas in patients receiving tamoxifen. Clin Exp Obstet Gynecol 1994; 21: 94-8.
45. Lim CK, Yuan ZX, Lamb JH, White IN, De Matteis F, Smith LL. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 1994; 15: 589-93.
46. Lion J, Hatton F, Maguin P, Maujol L. Statistiques de santé: statistiques des causes médicales de décès. Paris: INSERM, 1990.
47. Love RR. Antiestrogens as chemopreventive agents in breast cancer: promise and issues in evaluation. Prev Med 1989; 18: 661-71.
48. Love RR. Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 1990; 82: 18-21.
49. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, DeMets DL. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860-4.
50. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-6.
51. Lutz JM, Chouillet AM, Coleman MP. Endometrium cancer after tamoxifen for breast cancer: a population-based case-control study [abstract no C23]. Réunion du Groupe pour l'épidémiologie et l'enregistrement du cancer dans les pays de langue latine. Abstracts. Granada: 1994; 24.
52. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11: 485-90.
53. Malfetano JH. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990; 39: 82-4.
54. Manni A, Pearson OH. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 1980; 64: 779-85.
55. Mani C, Pearce R, Parkinson A, Kupfer D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 1994; 15: 2715-20.
56. Morgan MA, Gincherman Y, Mikuta JJ. Endometriosis and tamoxifen therapy. Int J Gynaecol Obstet 1994; 45: 55-7.
57. Neven P, De Muylder X, Van Belle Y, Vanderick C, De Muylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 1990; 35: 235-8.
58. Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barron B, Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989; 8: 125-31.
59. Pathak DN, Bodell WJ. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 1994; 15: 529-32.
60. Randerath K, Moorthy B, Mabon N, Sriram P. Tamoxifen: evidence by 32P-postlabelling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and idenfication of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 1994; 15: 2087-94.
61. Rudigoz RC. Endomètres et antiœstrogènes. Reprod Hum Horm 1994; 7: 201-17.
62. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995; 87: 645-51.
63. Saez S. Utilisation des antiœstrogènes dans le cancer du sein. Lettre du gynécologue 1989; 113: 2-4.
64. Saez S, Sasco AJ. Difficultés de la transposition en thérapeutique des activités biologiques analysées in vitro: l'exemple du tamoxifène. In: Martin PM, ed. Biologie du cancer du sein: progrès récents. Tome I. Cancer du sein: 20 ans de progrès. Neuville-sur-Seine: Publications Médicales Internationales, 1995; 177-80.
65. Sasco AJ. Quelques réflexions sur le rôle cancérogène potentiel du tamoxifène. Bull Cancer 1994; 81: 706-14.
66. Sasco AJ. Tamoxifen and menopausal status: risks and benefits. Lancet 1996; 347: 761.
67. Sasco AJ, Ah-Song R, Saez S, Kuttenn F. Effets secondaires d'une intervention de chimioprévention: l'exemple du tamofixène. Bull Cancer 1995a; 82 (suppl. 3): 186-206.
68. Sasco AJ, Chaplain G, Saez S, Amoros E. Case-control study of endometrial cancer following breast cancer. Effect of tamoxifen and radiotherapeutic castration. Am J Epidemiol 1995b; 141: 578.
69. Sasco AJ, Raffi F, Satgé D, Goburdhun J, Fallouh B, Leduc B. Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int J Gynaecol Obstet 1995c; 48: 307-10.
70. Sasco AJ, Chaplain G, Amoros E, Saez S. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 1996; 7: 9-13.
71. Seoud MA, Johnson J, Weed JC. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993; 82: 165-9.
72. Silva EG, Tornos CS, Follen Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 1994; 13: 248-58.
73. Spicer DV, Pike MC, Henderson BE. Ovarian cancer and long-term tamoxifen in premenopausal women [letter]. Lancet 1991; 337: 1414.
74. Terada S, Uchide K, Suzuki N, Akasofu K. A follicular cyst during tamoxifen therapy in a premenopausal breast cancer woman. Gynecol Obstet Invest 1993; 35: 62-4.
75. Touraine P, Driguez P, Cartier I, Yaneva II, Kuttenn F, Mauvais Jarvis P. Lack of induction of endometrial hyperplasia with tamoxifen [letter]. Lancet 1995; 345: 254-5.
76. Ueo H, Matsuoka H, Honda M, Inoue H, Takaki R, Akiyoshi T. Chemopreventive effects of tamoxifen in ethyl methanesulphonate-induced rat mammary carcinogenesis. Cancer Lett 1993; 71: 19-24.
77. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbai M, Diepenhorst FW, van den Belt-Dusebout AW, van Tinteren H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448-52.
78. Vancutsem PM, Lazarus P, Williams GM. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 1994; 54: 3864-7.
79. Vogel VG, Saenz M. Tamoxifen for the prevention of breast cancer: yes. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott, 1995; 187-200.
80. WHO. Essential drugs for cancer chemotherapy: memorandum from a WHO meeting. Bull WHO 1985; 63: 999-1002.
81. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14: 315-7.
82. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167-70.